Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer

NCT02448771 is registered in ClinicalTrials.gov with Dana-Farber Cancer Institute as lead sponsor.

NCT NCT02448771
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02448771 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer
Lead sponsor
Dana-Farber Cancer Institute
Phase
Phase 1/2
Overall status
Completed
Start date
July 9, 2015
Completion date
March 3, 2021
Enrollment
36 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer stage iv, metastatic invasive breast cancer, unresectable locally advanced invasive breast cancer